↓ Skip to main content

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development

Overview of attention for article published in Journal of Hematology & Oncology, September 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
2 news outlets
twitter
1 X user
patent
6 patents

Citations

dimensions_citation
389 Dimensions

Readers on

mendeley
69 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
Published in
Journal of Hematology & Oncology, September 2018
DOI 10.1186/s13045-018-0664-7
Pubmed ID
Authors

Guoshuang Shen, Fangchao Zheng, Dengfeng Ren, Feng Du, Qiuxia Dong, Ziyi Wang, Fuxing Zhao, Raees Ahmad, Jiuda Zhao

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 69 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 11 16%
Student > Ph. D. Student 8 12%
Unspecified 6 9%
Student > Postgraduate 5 7%
Other 4 6%
Other 9 13%
Unknown 26 38%
Readers by discipline Count As %
Medicine and Dentistry 14 20%
Biochemistry, Genetics and Molecular Biology 13 19%
Unspecified 6 9%
Agricultural and Biological Sciences 2 3%
Chemistry 2 3%
Other 4 6%
Unknown 28 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 30. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 April 2024.
All research outputs
#1,336,762
of 25,782,229 outputs
Outputs from Journal of Hematology & Oncology
#69
of 1,305 outputs
Outputs of similar age
#27,879
of 352,703 outputs
Outputs of similar age from Journal of Hematology & Oncology
#1
of 20 outputs
Altmetric has tracked 25,782,229 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,305 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.5. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,703 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.